Phase 1/2 dose escalation and expansion study evaluating MCLA-129, a human anti-EGFR and anti-c-MET bispecific antibody, in patients with advanced NSCLC and other solid tumors

Status

Recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514461-19-00

Acronym

MCLA-129-CL01

Enrollment

238

Registered

2024-10-14

Start date

2021-09-09

Completion date

Unknown

Last updated

2025-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid Tumors

Brief summary

Objective Response Rate (ORR), Frequency and severity of adverse events, serious adverse events, treatment discontinuations and modifications, Pharmacokinetic parameters (CEOI, Cmax, C0h, AUC, CL, Vss, tmax and t1/2,) and population pharmacokinetics, Progression-Free Survival (PFS) and Duration of Response (DOR), Overall Survival (OS)

Interventions

DRUGPACLITAXEL

DRUGDOCETAXEL

DRUGOSIMERTINIB

DRUGCARBOPLATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Objective Response Rate (ORR), Frequency and severity of adverse events, serious adverse events, treatment discontinuations and modifications, Pharmacokinetic parameters (CEOI, Cmax, C0h, AUC, CL, Vss, tmax and t1/2,) and population pharmacokinetics, Progression-Free Survival (PFS) and Duration of Response (DOR), Overall Survival (OS)	—

Countries

Belgium, France, Germany, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026